Navigation Links
Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
Date:4/18/2013

BLUE BELL, Pa., April 18, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that it was presented Vaccine Industry Excellence (ViE) Awards for "Best Therapeutic Vaccine" and "Best Early Stage Biotech" at the World Vaccine Congress, which is being held this week in Washington, D.C. The ViE Awards recognize outstanding vaccine advancements and achievements of vaccine developers across the global industry as judged by a panel of global biotech industry stakeholders.

The "Best Therapeutic Vaccine" award recognized Inovio's DNA vaccine designed to treat HPV-caused cervical dysplasia, VGX-3100. In human studies this therapeutic vaccine has demonstrated that it not only drives robust immune responses to antigens from high risk types of human papillomavirus (HPV) infection but that these immune responses display a powerful killing effect against cells changed by HPV into precancerous dysplasias. This desirable effect may ultimately contribute to the regression or elimination of cervical dysplasia, cervical cancer, and other cancers caused by HPV. These data have been published in the peer-reviewed journal, Science-Translational Medicine. Inovio is currently assessing the ability of its DNA-based VGX-3100 to treat cervical dysplasias caused by HPV infection in a global phase II trial, with results expected in the first quarter of 2014.

The "Best Early Stage Biotech" award highlights Inovio's pioneering advancement of its proprietary SynCon® DNA vaccine and electroporation delivery technologies. Its expanding product pipeline includes clinical programs for HPV-caused dysplasia and cancers, influenza, and HIV, and preclinical programs for hepatitis C virus, hepatitis B virus, prostate cancer, mala
'/>"/>

SOURCE Inovio Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Inovio Pharmaceuticals to Present at SPI 2012
4. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
5. Inovio Pharmaceuticals to Present at JMP Investor Conference
6. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
7. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
8. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
10. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
11. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Chiasma, Inc. (NASDAQ: ... octreotide capsules for the orphan condition acromegaly, today ... June 30, 2015 and provided a corporate update. ... a transformative time for Chiasma, as we successfully ... that our first New Drug Application (NDA) has ...
(Date:8/31/2015)... 2015 A new Transparency ... monitoring and diagnostic devices market stood at US$3.7 ... a value of approximately US$7.0 billion in 2019, ... and 2019. The title of the report is ... Monitors, Event Monitors, Cardiovascular Diagnostic Catheters, Implantable Loop ...
(Date:8/31/2015)... YORK , Aug. 31, 2015  Dipexium Pharmaceuticals, ... focused on the development and commercialization of Locilex® (pexiganan ... today announced plans to participate in four investor conferences ... 2, 2015 at the Sidoti & Company, LLC Emerging ... . David P. Luci , President & ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... announces the appointment of Susan C. Stansfield, PhD ... Development. In this position, Dr. Stansfield will have ... clinical trial management services provided to the biopharmaceutical ... proven leadership skills will be pivotal in enhancing ...
... Reportlinker.com announces that a new market research ... E7: The Outlook for Pharmaceuticals to ... The emerging E7 countries represent the ... these countries is huge: they have a ...
Cached Medicine Technology:Premier Research Names Susan Stansfield, PhD Executive VP, Clinical Development 2E7: The Outlook for Pharmaceuticals to 2012 2E7: The Outlook for Pharmaceuticals to 2012 3E7: The Outlook for Pharmaceuticals to 2012 4E7: The Outlook for Pharmaceuticals to 2012 5
(Date:9/1/2015)... Calif. (PRWEB) , ... September 01, 2015 , ... ... today that Brent Nelson, D.O., has joined its medical management team as an ... serving companies of all sizes and types in the U.S. and abroad. ...
(Date:9/1/2015)... , ... September 01, 2015 , ... SC&H Group, a ... which includes being named a “Best of the Best” firm in the U.S., as ... named the “Best of the Best” in the U.S., selected exclusively on performance in ...
(Date:9/1/2015)... ... ... Mercy Health (formerly Catholic Health Partners) – a Catholic healthcare ministry serving Ohio ... Be Well videos to prostate cancer awareness. Prostate cancer is the most-common, non-skin cancer ... Mercy Health’s YouTube channel, Mercy Health experts address issues, such as:, ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... its consumer-friendly, informational video this week to coincide with back-to-school and the start ... , According to the CDC, elementary school children are sick an average of ...
(Date:9/1/2015)... ... September 01, 2015 , ... Dr. Trace Curry successfully placed one of ... In the last month the FDA has approved two intra-gastric balloons, the ORBERA ... represent the first incisionless, reversible, weight loss procedures available to Americans. , ...
Breaking Medicine News(10 mins):Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2Health News:USA Medical Card Launches New FAQ Video During Back-to-School 2Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2
... HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay News) -- Giving ... early as 23 weeks during their pregnancy may boost an ... of serious developmental issues, including brain injury, a new study ... of the Journal of the American Medical Association , ...
... 6 (HealthDay News) -- U.S. officials on Tuesday said that ... labeled HCG weight loss products from the market. HCG ... human placenta and found in the urine of pregnant women. ... low-calorie diet -- as low as 500 calories per day ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, Dec. ... being treated with hormone therapy do not appear to be ... a large new review of evidence. Hormone therapy ... treatment. Several previous studies found that the therapy might increase ...
... pain may experience greater relief if their doctors add ... marijuana to an opiates-only treatment. The findings, from ... could result in reduced opiate dosages. More than ... people than diabetes, heart disease and cancer combined, according ...
... Museum in Indianapolis may find the 19th-century brains on ... an insane asylum, but a recent breakthrough using these ... of Medicine could spell the future of detecting mental ... professor of pathology and laboratory science at the IU ...
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, ... with their close relatives, an adaptation that not only ups ... to thrive, two new studies find. Entomologists from North ... taken from infested apartment buildings in North Carolina and New ...
Cached Medicine News:Health News:Steroids May Boost Survival for Very Preemie Babies 2Health News:FDA Targets Homeopathic Weight Loss Products 2Health News:FDA Targets Homeopathic Weight Loss Products 3Health News:FDA Targets Homeopathic Weight Loss Products 4Health News:Hormone Drugs Might Not Raise Heart-Related Deaths in Prostate Patients 2Health News:Hormone Drugs Might Not Raise Heart-Related Deaths in Prostate Patients 3Health News:UCSF study finds medical marijuana could help patients reduce pain with opiates 2Health News:UCSF study finds medical marijuana could help patients reduce pain with opiates 3Health News:Century-old brains may hold future of treatment for mentally ill, Indiana University pathologist says 2Health News:Century-old brains may hold future of treatment for mentally ill, Indiana University pathologist says 3Health News:Bed Bugs Can Bypass Pitfalls of Inbreeding, Studies Say 2Health News:Bed Bugs Can Bypass Pitfalls of Inbreeding, Studies Say 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: